A new Partnership to ignite change for sickle cell disease
Vertex Redesign
Stay updated with breaking news from Graphite Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Equities researchers at Cantor Fitzgerald issued their FY2022 earnings estimates for Graphite Bio in a report issued on Thursday, September 15th. Cantor Fitzgerald analyst O. Brayer forecasts that the company will post earnings per share of ($1.45) for the year. Cantor Fitzgerald currently has a “Overweight” rating […]
/PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological...
Keynote by Admiral Rachel Levine, M.D., Assistant Secretary for Health, U.S. Department of Health and Human Services...